Literature DB >> 9018134

Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.

E Konishi1, I Kurane, P W Mason, R E Shope, F A Ennis.   

Abstract

Recombinant Japanese encephalitis (JE) vaccine candidates based on a highly attenuated vaccinia virus (NYVAC-JEV) and a canarypox virus (ALVAC-JEV) were evaluated for their ability to induce specific antibodies and cytotoxic T lymphocytes (CTLs) in mice. Six- to eight-week-old male Balb/c mice that received one or two intraperitoneal inoculations with these JE vaccine candidates at a dose of 1 x 10(7) PFU per mouse produced neutralizing antibody and antibodies to the envelope (E) and nonstructural 1 (NS1) proteins as determined by radioimmunoprecipitation. Immunization with either of these vaccine candidates also induced JE virus-specific T lymphocytes that proliferated in response to stimulation with infectious virus and/or noninfectious viral antigens. Mice maintained detectable levels of neutralizing antibody and JE virus-specific memory T cells for at least 6 months after immunization with NYVAC-JEV and for 4 months after immunization with ALVAC-JEV. Cells induced to proliferate after stimulation with live virus contained specific CD8+ CTLs that lysed primary Balb/c mouse kidney cells infected with JE virus and P815 mastocytoma cells infected with a recombinant vaccinia virus expressing the premembrane (prM), E, and NS1 proteins. These CTLs also lysed P815 cells infected with vaccinia recombinants expressing prM and E, and those expressing E and NS1, but did not lyse P815 cells infected with a recombinant virus expressing only NS1, indicating that the CTLs mainly recognized E, but did not recognize NS1. These results demonstrate that both recombinant JE vaccines, NYVAC-JEV and ALVAC-JEV, induce JE virus-specific antibody and CTLs in mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018134     DOI: 10.1006/viro.1996.8331

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Authors:  Wenling Wang; Renqing Li; Yao Deng; Ning Lu; Hong Chen; Xin Meng; Wen Wang; Xiuping Wang; Kexia Yan; Xiangrong Qi; Xiangmin Zhang; Wei Xin; Zhenhua Lu; Xueren Li; Tao Bian; Yingying Gao; Wenjie Tan; Li Ruan
Journal:  Clin Vaccine Immunol       Date:  2015-04-01

2.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

Authors:  Toshio Naito; Yutaro Kaneko; Danuta Kozbor
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

3.  Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes.

Authors:  T Liu; T J Chambers
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses.

Authors:  C H Pan; H W Chen; H W Huang; M H Tao
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.

Authors:  I M Belyakov; B Moss; W Strober; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

7.  The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.

Authors:  E Konishi; M Yamaoka; I Kurane; K Takada; P W Mason
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Production of pseudoinfectious yellow fever virus with a two-component genome.

Authors:  Alexandr V Shustov; Peter W Mason; Ilya Frolov
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

10.  The blood-brain barrier in the cerebrum is the initial site for the Japanese encephalitis virus entering the central nervous system.

Authors:  Tsan-Hsiun Liu; Li-Ching Liang; Chien-Chih Wang; Huei-Chung Liu; Wei-June Chen
Journal:  J Neurovirol       Date:  2008-11       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.